表紙
市場調査レポート

NewLink Genetics Corporation:製品パイプライン分析

NewLink Genetics Corporation - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224685
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
NewLink Genetics Corporation:製品パイプライン分析 NewLink Genetics Corporation - Product Pipeline Review - 2016
出版日: 2016年04月27日 ページ情報: 英文 53 Pages
概要

NewLink Genetics Corporation は、様々な癌の症状を治療する免疫療法製品を開発するバイオ製薬会社です。

当レポートでは、NewLink Genetics Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

NewLink Genetics Corporationの基本情報

  • NewLink Genetics Corporationの概要
  • 主要情報
  • 企業情報

NewLink Genetics Corporation:R&Dの概要

  • 主な治療範囲

NewLink Genetics Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

NewLink Genetics Corporation:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

NewLink Genetics Corporation:薬剤プロファイル

  • algenpantucel-L
  • tergenpumatucel-L
  • dorgenmeltucel-L
  • indoximod
  • 前立腺癌向けHyperAcute
  • 腎臓癌向けHyperAcute
  • インフルエンザワクチン
  • 癌治療のためのIDOおよびTDOを阻害する小分子
  • 癌治療のためのIDOの経路を阻害する小分子
  • 癌治療のためのTDOを阻害する小分子
  • 黄熱病/アレナウィルスワクチン

NewLink Genetics Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

NewLink Genetics Corporation:最近のパイプライン動向

NewLink Genetics Corporation:休止中のプロジェクト

NewLink Genetics Corporation:企業発表

NewLink Genetics Corporation:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08037CDB

Summary

Global Markets Direct's, 'NewLink Genetics Corporation - Product Pipeline Review - 2016', provides an overview of the NewLink Genetics Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NewLink Genetics Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of NewLink Genetics Corporation
  • The report provides overview of NewLink Genetics Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses NewLink Genetics Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features NewLink Genetics Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate NewLink Genetics Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for NewLink Genetics Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NewLink Genetics Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NewLink Genetics Corporation Snapshot
    • NewLink Genetics Corporation Overview
    • Key Information
    • Key Facts
  • NewLink Genetics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • NewLink Genetics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • NewLink Genetics Corporation - Pipeline Products Glance
    • NewLink Genetics Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • NewLink Genetics Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • NewLink Genetics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • NewLink Genetics Corporation - Drug Profiles
    • algenpantucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indoximod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tergenpumatucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dorgenmeltucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Hormone Refractory Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H1N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit IDO and TDO for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit TDO for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (arenavirus + yellow fever) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Zika virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NewLink Genetics Corporation - Pipeline Analysis
    • NewLink Genetics Corporation - Pipeline Products by Target
    • NewLink Genetics Corporation - Pipeline Products by Route of Administration
    • NewLink Genetics Corporation - Pipeline Products by Molecule Type
    • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action
  • NewLink Genetics Corporation - Recent Pipeline Updates
  • NewLink Genetics Corporation - Dormant Projects
  • NewLink Genetics Corporation - Company Statement
  • NewLink Genetics Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NewLink Genetics Corporation, Key Information
  • NewLink Genetics Corporation, Key Facts
  • NewLink Genetics Corporation - Pipeline by Indication, 2016
  • NewLink Genetics Corporation - Pipeline by Stage of Development, 2016
  • NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016
  • NewLink Genetics Corporation - Combination Treatment Modalities in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • NewLink Genetics Corporation - Phase III, 2016
  • NewLink Genetics Corporation - Phase II, 2016
  • NewLink Genetics Corporation - Phase I, 2016
  • NewLink Genetics Corporation - Preclinical, 2016
  • NewLink Genetics Corporation - Discovery, 2016
  • NewLink Genetics Corporation - Pipeline by Target, 2016
  • NewLink Genetics Corporation - Pipeline by Route of Administration, 2016
  • NewLink Genetics Corporation - Pipeline by Molecule Type, 2016
  • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016
  • NewLink Genetics Corporation - Recent Pipeline Updates, 2016
  • NewLink Genetics Corporation - Dormant Developmental Projects,2016
  • NewLink Genetics Corporation, Other Locations
  • NewLink Genetics Corporation, Subsidiaries

List of Figures

  • NewLink Genetics Corporation - Pipeline by Top 10 Indication, 2016
  • NewLink Genetics Corporation - Pipeline by Stage of Development, 2016
  • NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016
  • NewLink Genetics Corporation - Pipeline by Target, 2016
  • NewLink Genetics Corporation - Pipeline by Route of Administration, 2016
  • NewLink Genetics Corporation - Pipeline by Molecule Type, 2016
  • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016
Back to Top